AMZN
Amazon.com, Inc.
AMZN has the edge over DORM overall, supported by stronger modeled upside and stronger fundamentals.
DORM
Dorman Products, Inc.
DORM's outlook is improving, though it still trails on the overall score.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
DORM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
DORM's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over DORM in the historical PE scenario, which offers more potential upside but is not a forecast.
DORM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $132 | — |
| Cheap | 19x | $125 | -5.6% |
| Current | 20x | $132 | — |
| Fair | 23x | $152 | +15% |
| Expensive | 28x | $191 | +45% |
Historical ranges are pointers, not guarantees.
DORM's PE is in its cheap range at 20x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
DORM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect DORM's earnings to grow and its profitability to improve, with its revenue holding steady.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over DORM on earnings, with more consistent year-over-year improvement.
DORM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.63 | +28% |
| Q3 2026 | $6.72 | -16% |
| Q2 2026 | $7.22 | -1.6% |
| Q1 2026 | $6.20 | -11% |
| Q4 2025 | $6.64 | +8.1% |
| Q3 2025 | $8.02 | +34% |
| Q2 2025 | $7.34 | +34% |
| Q1 2025 | $6.96 | +40% |
| Q4 2024 | $6.14 | +50% |
DORM earned $6.72 per share over the past year, down 16% from the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over DORM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN's operating margin was 14% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
DORM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $561.7M | +3.3% |
| Q2 2026 | $544.6M | +0.7% |
| Q1 2026 | $528.8M | +4.2% |
| Q4 2025 | $537.9M | +0.8% |
| Q3 2025 | $543.7M | +7.9% |
| Q2 2025 | $541M | +7.6% |
| Q1 2025 | $507.7M | +8.3% |
| Q4 2024 | $533.8M | +8% |
DORM's revenue has grown year over year for 11 quarters in a row: $562M last quarter, up 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -4.7 points |
| Q2 2026 | 21% | +6.1 points |
| Q1 2026 | 11% | -4.7 points |
| Q4 2025 | 5.8% | -10 points |
| Q3 2025 | 19% | +3.7 points |
| Q2 2025 | 15% | +0.8 points |
| Q1 2025 | 16% | +4.2 points |
| Q4 2024 | 16% | +0.6 points |
DORM has the edge over AMZN on profitability, with a higher operating margin.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
DORM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $56.9M | +3022% |
| Q2 2026 | $143.5M | +146376% |
| Q1 2026 | $35.3M | -12% |
| Q4 2025 | $33.5M | -47% |
| Q3 2025 | $1.8M | -95% |
| Q2 2025 | $98K | -100% |
| Q1 2025 | $40.3M | -2.4% |
| Q4 2024 | $63.2M | +30% |
DORM has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
DORM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -135K shares |
| 1 year | -3% | -922K shares |
| 3 years | -5.4% | -1.7M shares |
| 5 years | -6.2% | -2M shares |
| Available history | -8.7% | -2.8M shares |
DORM has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over DORM on leverage, with a lower net debt burden relative to earnings.
DORM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.8x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.2x | Healthy |
DORM's net debt is less than a year of its operating earnings (EBITDA).
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
DORM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.7 | Neutral |
| Stochastic | 49.5 | Neutral |
DORM's weekly RSI is 54 (neutral) and its Stochastic is 50 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
DORM PE vs Consumer Cyclical Sector
| Metric | DORM | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 18x | 9% above |
| PE % | 24 | 47 | 23 pts below |
DORM has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN is in an uptrend: it's above all five of its weekly moving averages, and 40% above its 200-week average.
DORM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $127.7 | 3.4% above |
| 20 week MA | $131.3 | 0.5% above |
| 50 week MA | $124.6 | 5.9% above |
| 100 week MA | $128.6 | 2.7% above |
| 200 week MA | $110.3 | 20% above |
DORM is in an uptrend: it's above all five of its weekly moving averages, and 20% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over DORM on returns for 2026, with the stronger performance.
DORM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $75.1 | $89.6 | +19% |
| 2021 | $89.6 | $106.4 | +19% |
| 2022 | $106.4 | $81.3 | -24% |
| 2023 | $81.3 | $83.4 | +2.6% |
| 2024 | $83.4 | $132.2 | +58% |
| 2025 | $132.2 | $126.6 | -4.2% |
| 2026 YTD | $126.6 | $132.0 | +4.2% |
DORM has finished higher in four of the last six years. It's up 4.2% so far in 2026.